AI Insight: Phibro Animal Health's current price exceeds the high-confidence fair value by 23.8%, indicating potential overvaluation amid mixed valuation signals, especially a negative DCF midpoint contrasted with strong analyst targets. Financial health is fair but marred by weak leverage and growth scores, while Monte Carlo analysis reveals high volatility and 97.1% downside risk. This suggests elevated investment risk despite solid profitability and liquidity.